Real-world 24-month pain outcomes of disk percutaneous ablation and extraction versus Disc-FX nucleoplasty for lumbar discogenic pain and contained lumbar disk herniation: a single-center retrospective cohort study - Takeaways - MDSpire

Real-world 24-month pain outcomes of disk percutaneous ablation and extraction versus Disc-FX nucleoplasty for lumbar discogenic pain and contained lumbar disk herniation: a single-center retrospective cohort study

  • By

  • Xiaohui Yang

  • Jiaxiang Ni

  • June 23, 2026

  • 0 min

Share

  • 1

    The study compared long-term outcomes of disk percutaneous ablation and extraction (DPAE) and Disc-FX in patients with lumbar discogenic pain.

  • 2

    At 24 months, the DPAE group showed a greater reduction in VAS scores compared to the Disc-FX group, with a mean difference of 1.05 points.

  • 3

    DPAE demonstrated superior outcomes in Oswestry Disability Index, Patient Global Impression of Change, and composite treatment success rates.

  • 4

    The reintervention rate was lower in the DPAE group at 7.3% compared to 14.8% in the Disc-FX group, indicating reduced reintervention risk.

  • 5

    Complication rates between DPAE and Disc-FX were not statistically significant, with rates of 6.4% and 9.1%, respectively.

Original Source(s)

Real-world 24-month pain outcomes of disk percutaneous ablation and extraction versus Disc-FX nucleoplasty for lumbar discogenic pain and contained lumbar disk herniation: a single-center retrospective cohort study

  • by Xiaohui Yang, Jiaxiang Ni

  • June 23, 2026

Related Content

Pain sensitization as a potentially modifiable factor in people with knee osteoarthritis: insights from behavioral graded activity

Efficacy analysis of robot-assisted percutaneous kyphoplasty in the treatment of osteoporotic vertebral compression fractures

Side Effects: Sour Mouth, Lower BP

Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.